Given that MTI drugs are important chemotherapeutic agents involved in treatment of leukemia, lymphomas, non-small cell lung cancer, breast cancer, testicular cancer and head and neck cancer, understanding MEKK1 activation within the context of apoptosis will improve chemotherapy regimens and outcomes [3], [4]. The gene discussed is MAP3K1; the disease is lymphoma.